NRD
TMDX icon

Nebula Research & Development’s Transmedics TMDX Stock Holding History

Nebula Research & Development’s Portfolio TMDX Stock Details TMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,827
Closed -$325K – 1154
2025
Q1 		$325K Buy
+4,827
New +$332K 0.03% 738
2024
Q2 		– Sell
-17,656
Closed -$1.31M – 1044
2024
Q1 		$1.31M Buy
+17,656
New +$1.46M 0.28% 80

Other funds holding TMDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nebula Research & Development's TMDX Position: Q2 2025 in Review

Nebula Research & Development sold out of Transmedics (TMDX) in Q2 2025, closing a stake of 4,827 shares — an estimated $325K sold.

Nebula Research & Development first reported a position in TMDX in Q1 2024 and held it in 2 quarters. The position peaked at $1.31M in Q1 2024. 368 funds tracked by Wall St. Rank hold TMDX as of Q2 2025.

  • Nebula Research & Development reported no remaining Transmedics position as of Q2 2025 after selling out during the quarter.
  • Nebula Research & Development sold 4,827 Transmedics shares in Q2 2025, an estimated $325K.
  • Nebula Research & Development first reported a position in Transmedics in Q1 2024 and held it in 2 quarters.
  • Nebula Research & Development's Transmedics position peaked at $1.31M in Q1 2024.
  • 368 funds tracked by Wall St. Rank held Transmedics as of Q2 2025.

Based on Nebula Research & Development's 13F filing for Q2 2025, filed 14 Aug 2025.